enVVeno Medical is restarting its entire franchise after the Food and Drug Administration refused to approve the surgical valve the company spent years building. The not-approvable letter last August, and the denied appeal in November, ended VenoValve as a commercial path and forced a full pivot onto enVVe, a catheter-delivered replacement valve that has never been implanted in a human. The market's answer is a cash discount. Mid-year cash and investments of $21.5 million sit against a capitalization near $6.2 million.
What changed in the second quarter is not the income statement. It is the regulatory door. Late April the agency granted an investigational device exemption for TAVVE, the first United States pivotal study of a non-surgical replacement venous valve. The protocol stages a ten-patient safety lead-in before a randomized comparison. A later cohort of 220 patients splits between device and standard care. The primary efficacy plan now includes regurgitant volume rather than relying on clinical scores alone. That last design choice is the entire investment debate. The agency rejected VenoValve because revised Venous Clinical Severity Score gains, even large ones, did not come with a hemodynamic measurement that correlated with how patients felt.
Second-quarter net loss compressed to $3.6 million as VenoValve follow-up spending rolled off and last year's stock-compensation and severance items did not repeat. Cash burn of $3.4 million stayed inside the recent quarterly band. Management describes runway into the third quarter of next year even after burn steps up when enrollment starts. The question the next several quarters resolve is whether the first ten implants clear the thirty-day safety gate, or whether the remaining cash is simply spent down while a second agency cycle repeats the first.